Clinical trials: Lung Cancer Non-Small Cell Cancer (NSCLC)
Resectable Non-Small Cell Lung Cancer
Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
This is an open label phase 2 clinical trial evaluating the clinical safety, feasibility and efficacy of neoadjuvant Adagrasib alone or in combination with nivolumab in patients with NSCLC with KRAS G12C mutation.
- Trial name
- Neo-Kan (NCT05472623)
- Testing
- Adagrasib, Adagrasib/Nivolumab
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small Cell Lung Cancer
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
This is a Phase III, single arm, multicenter study designed to evaluate the efficacy and safety of atezolizumab in high PD-L1 expression, chemotherapy-naïve, without a sensitizing EGFR mutation or ALK translocation patients with…
- Trial name
- NCT05047250
- Testing
- Atezolizumab
- Where
- 18 sites in China
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma
Determine whether patients have a decreased incidence of grade 3 and grade 4 neutropenia when Filgrastim-SD/01 is given with docetaxel and gemcitabine in patients with advanced non-small cell lung cancer.
- Trial name
- NCT00050674
- Testing
- Filgrastim-SD/01
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Schwartzberg, Lee, M.D.
Metastatic Non Small Cell Lung Cancer
This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer
This clinical trial is comparing morning infusions of the study drug (pembrolizumab) to random infusion scheduling for patients with non-small cell lung cancer.
- Trial name
- TIME-NSCLC (NCT06882174)
- Testing
- Scheduling of the time of pembrolizumab infusions
- Volunteers
- 58 people
- Sponsor
- AHS Cancer Control Alberta
Stage III Malignant Mesothelioma, Stage IIIB Non-small Cell Lung Cancer
Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy
This pilot clinical trial studies photodynamic therapy during surgery in treating patients with pleural (the protective lining or membrane that covers the lungs and chest cavity) malignancy.
- Conditions
- Stage III Malignant Mesothelioma, Stage IIIB Non-small Cell Lung Cancer, Stage IV Malignant Mesothelioma, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT02106559
- Testing
- porfimer sodium, therapeutic conventional surgery, photodynamic therapy
- Sponsor
- Ohio State University Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung, Bone Metastases
Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)
Bone metastases are common in Non-Small Cell Lung Cancer (NSCLC). They most often occur during disease progression. It is thought that more than half of the patients with bone metastases will have at least 1 skeletal-related…
- Trial name
- DENIVOS (NCT03669523)
- Testing
- Denosumab-nivolumab combination
- Where
- 27 sites in France
- Volunteers
- 82 people
- Sponsor
- Centre Hospitalier Annecy Genevois
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)
This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy.
- Trial name
- MERIT (NCT02774278)
- Testing
- Erlotinib
- Where
- 29 sites in Belgium, Bulgaria and 12 more
- Volunteers
- 264 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab
This is a phase 2 multicenter, open label, randomized study of AMG 951 (rhApo2L/TRAIL) in subjects with previously untreated stage IIIb/IV NSCLC treated with chemotherapy with or without bevacizumab.
- Trial name
- NCT00508625
- Testing
- AMG 951 (rhApo2L/TRAIL), Bevacizumab, Carboplatin
- Volunteers
- 213 people
- Sponsor
- Amgen
Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic
MGD019 DART® Protein in Unresectable/Metastatic Cancer
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab.
- Conditions
- Squamous Cell Non Small Cell Lung Cancer, Prostate Cancer Metastatic, Cutaneous Melanoma, Colorectal Cancer
- Trial name
- NCT03761017
- Testing
- Lorigerlimab
- Where
- 39 sites in United States, Bulgaria and 3 more
- Volunteers
- 162 people
- Sponsor
- MacroGenics
Non-small Cell Lung Cancer
Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
This is a prospective, single arm study to investigate the efficacy and safety furmonertinib 80mg/d as adjuvant treatment for 3 years post surgery of stage IA with high-risk factors and stage IB non-small cell lung cancer.
- Trial name
- NCT05445310
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Peking Union Medical College Hospital
Carcinoma, Non-Small-Cell Lung
Drug-eluting Beads Bronchial Arterial Chemoembolization in Stage II-III Non-small-cell Lung Cancer Patients Failed, Refused or Ineligible to Receive Standard Treatments
This is a multicenter, prospective, single-arm clinical study to determine the efficacy and safety of Drug-eluting beads bronchial arterial chemoembolization（DEB-BACE） in stage II-III NSCLC patients who failed, refused or…
- Trial name
- NCT04825925
- Testing
- DEB-BACE(Drug-eluting beads bronchial arterial chemoembolization)
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non Hodgkin Lymphoma, Non Small Cell Lung Cancer
Integrated Discovery of New Immuno-Molecular Actionable Biomarkers for Tumors With Immune-suppressed Environment
The explosion of novel therapies targeting tumor mutations or immune molecules requests to define or better characterize the mutational profiles of tumors that are none or insufficiently explored so far.
- Conditions
- Non Hodgkin Lymphoma, Non Small Cell Lung Cancer, Glioma
- Trial name
- IDeATIon (NCT03706625)
- Where
- France
- Volunteers
- 201 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC)
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
The goal of this clinical trial is to evaluate the diagnostic value of CAIX protein specific probe 18F-T2 in PET/CT imaging in participants with solid tumors.
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer
- Trial name
- NCT07557225
- Testing
- 18F-T2 PET/CT
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Non Small Cell Lung Cancer
Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC
Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be…
- Trial name
- NCT02005120
- Testing
- Bevacizumab, recombinant human endostatin
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Non-small Cell Lung Cancer
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age…
- Trial name
- NCT06745882
- Testing
- Cisplatin, Carboplatin, Pemetrexed
- Where
- 11 sites in United States
- Volunteers
- 318 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leptomeningeal Metastasis, Leptomeningeal Disease
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
The FORESEE Study is a multi-center, prospective clinical trial enrolling patients with Breast or Non-Small Cell Lung Cancer (NSCLC) who have suspicious or confirmed Leptomeningeal Metastases (LM).
- Conditions
- Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Breast Cancer
- Trial name
- FORESEE (NCT05414123)
- Testing
- CNSide
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Biocept, Inc.
Metastatic Colorectal Cancer, Metastatic Cervical Cancer
Safety of Effivia®, a Bevacizumab Biosimilar
This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
- Conditions
- Metastatic Colorectal Cancer, Metastatic Cervical Cancer, Non Squamous Non Small Cell Lung Cancer
- Trial name
- NCT06313268
- Testing
- Bevacizumab Biosimilar MB02
- Where
- 5 sites in Mexico
- Volunteers
- 83 people
- Sponsor
- Laboratorios Liomont
Non Small Cell Lung Cancer Stage
Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer
The hypothesis for this study is that hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with concurrent carboplatin and paclitaxel, followed by maintenance durvalumab will improve locoregional control at 18…
- Trial name
- NCT04992780
- Testing
- Hypo-Fractionation, Standard-Fractionation
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Kansas Medical Center
Lung Cancer
Totally Robotic Versus Surgeon-Assisted Robotic Lung Resection For Early-Stage NSCLC
Robotic-assisted thoracoscopic surgery (RTS) is safe and effective for patients with early-stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT06348030
- Testing
- Medtronic Signia Stapler, Vessel Sealer Extend Energy Device and SureForm Stapler
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Endometrial Cancer, Endometrial Cancer Recurrent
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab…
- Conditions
- Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer
- Trial name
- NCT02922764
- Testing
- RGX-104, Ipilimumab, Docetaxel
- Where
- 21 sites in United States
- Volunteers
- 146 people
- Sponsor
- Inspirna, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.